Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, closed a $10 million senior secured term loan with Oxford BioTherapeutics.Oxford Finance, Oxford BioTherapeutics
“Oxford Finance welcomes the opportunity to work alongside leading UK life sciences companies, like Oxford BioTherapeutics, to provide capital to support ongoing research in this field and bring novel therapies to the market,” said Christopher A. Herr, senior managing director at Oxford Finance. “We believe Oxford BioTherapeutics has a promising approach to identifying targets for the treatment of cancer, and we are encouraged by the progress of their current development programs for the treatment of acute myeloid leukemia and triple negative breast cancer.”
Oxford BioTherapeutics, based in Oxford, UK, is an international, clinical-stage biotechnology company developing antibody therapeutics for cancer.